Over 30 NDA/MAAs approved in virtual to large companies; last in 2020 in Breakthrough Therapy Designation. Ten years in R&D-commercialisation consultancy, licencing, developing and supply of 5 drugs from pharma companies to US start-up clients, three approved, two in Ph II/III, after major pharma acquisition. As VP Endocrinology Portfolio, Ipsen, led plan for SOMATULINE from €100M to >€1,000M; Held manufacturing strategy, industrial technology and product development leadership roles in Aventis, RPR, Fisons and Syntex. Non-Executive Director of Oval Medical Ltd until sale to SMC Ltd in 2016. He has BSc Hons Pharmacy and PhD from Robert Gordon University, Aberdeen.